Robert Wasserman
Stock Analyst at Benchmark
(3.22)
# 1,168
Out of 4,435 analysts
77
Total ratings
47.83%
Success rate
1.11%
Average return
Main Sectors:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRLB Proto Labs | Reiterates: Buy | $45 | $30.97 | +45.30% | 6 | May 29, 2024 | |
| INTS Intensity Therapeutics | Reiterates: Speculative Buy | $12 | $4.97 | +141.45% | 5 | May 16, 2024 | |
| NEPH Nephros | Reiterates: Speculative Buy | $5 | $2.18 | +129.36% | 2 | May 15, 2024 | |
| OABI OmniAb | Reiterates: Buy | $8 | $4.34 | +84.33% | 5 | May 14, 2024 | |
| BLFS BioLife Solutions | Upgrades: Buy | $25 | $21.48 | +16.39% | 5 | May 13, 2024 | |
| ITGR Integer Holdings | Reiterates: Buy | $130 | $121.24 | +7.23% | 5 | May 10, 2024 | |
| CDXS Codexis | Reiterates: Buy | $9 | $3.38 | +166.27% | 5 | May 3, 2024 | |
| TECH Bio-Techne | Reiterates: Buy | $95 | $77.19 | +23.07% | 4 | May 2, 2024 | |
| HALO Halozyme Therapeutics | Reiterates: Buy | $50 | $44.29 | +12.89% | 5 | Apr 16, 2024 | |
| LGND Ligand Pharmaceuticals | Reiterates: Buy | $95 | $85.05 | +11.70% | 6 | Apr 12, 2024 | |
| EBS Emergent BioSolutions | Reiterates: Buy | $5 | $5.70 | -12.28% | 9 | Apr 11, 2024 | |
| IPA ImmunoPrecise Antibodies | Reiterates: Speculative Buy | $5 | $1.11 | +350.69% | 4 | Mar 15, 2024 | |
| ATHE Alterity Therapeutics | Reiterates: Speculative Buy | $4 | $1.87 | +113.90% | 1 | Mar 7, 2024 | |
| PCSA Processa Pharmaceuticals | Reiterates: Speculative Buy | $4 | $1.48 | +170.27% | 1 | Mar 6, 2024 | |
| ABCL AbCellera Biologics | Upgrades: Buy | n/a | $3.92 | - | 3 | Feb 22, 2024 | |
| RGEN Repligen | Downgrades: Hold | n/a | $149.09 | - | 2 | Dec 4, 2023 | |
| ANEB Anebulo Pharmaceuticals | Reiterates: Speculative Buy | $8 | $2.05 | +290.24% | 4 | Oct 3, 2023 | |
| FBIO Fortress Biotech | Reiterates: Speculative Buy | $75 | $1.84 | +3,976.09% | 2 | Apr 6, 2023 | |
| DHR Danaher | Downgrades: Hold | n/a | $256.80 | - | 3 | Oct 24, 2022 |
Proto Labs
May 29, 2024
Reiterates: Buy
Price Target: $45
Current: $30.97
Upside: +45.30%
Intensity Therapeutics
May 16, 2024
Reiterates: Speculative Buy
Price Target: $12
Current: $4.97
Upside: +141.45%
Nephros
May 15, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $2.18
Upside: +129.36%
OmniAb
May 14, 2024
Reiterates: Buy
Price Target: $8
Current: $4.34
Upside: +84.33%
BioLife Solutions
May 13, 2024
Upgrades: Buy
Price Target: $25
Current: $21.48
Upside: +16.39%
Integer Holdings
May 10, 2024
Reiterates: Buy
Price Target: $130
Current: $121.24
Upside: +7.23%
Codexis
May 3, 2024
Reiterates: Buy
Price Target: $9
Current: $3.38
Upside: +166.27%
Bio-Techne
May 2, 2024
Reiterates: Buy
Price Target: $95
Current: $77.19
Upside: +23.07%
Halozyme Therapeutics
Apr 16, 2024
Reiterates: Buy
Price Target: $50
Current: $44.29
Upside: +12.89%
Ligand Pharmaceuticals
Apr 12, 2024
Reiterates: Buy
Price Target: $95
Current: $85.05
Upside: +11.70%
Emergent BioSolutions
Apr 11, 2024
Reiterates: Buy
Price Target: $5
Current: $5.70
Upside: -12.28%
ImmunoPrecise Antibodies
Mar 15, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $1.11
Upside: +350.69%
Alterity Therapeutics
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $1.87
Upside: +113.90%
Processa Pharmaceuticals
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $1.48
Upside: +170.27%
AbCellera Biologics
Feb 22, 2024
Upgrades: Buy
Price Target: n/a
Current: $3.92
Upside: -
Repligen
Dec 4, 2023
Downgrades: Hold
Price Target: n/a
Current: $149.09
Upside: -
Anebulo Pharmaceuticals
Oct 3, 2023
Reiterates: Speculative Buy
Price Target: $8
Current: $2.05
Upside: +290.24%
Fortress Biotech
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $1.84
Upside: +3,976.09%
Danaher
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $256.80
Upside: -